The expression of fibroblast activation protein in clear cell renal cell carcinomas is associated with synchronous lymph node metastases

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Errarte, Peio ^a,b   Guarch, Rosa ^c   Pulido, Rafael ^b,d   Blanco, Lorena ^b   Nunes Xavier, Caroline E ^b,e   Beitia, Maider ^a,b   Gil, Javier ^a,b   Angulo, Javier C ^f   Lopez, José I ^b,g   Larrinaga, Gorka ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^c Instituto de Investigación Sanitaria de Navarra   (Spain)

^d BASQUE FOUNDATION FOR SCIENCE   (Spain)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^g HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST ACTIVATION PROTEIN; SERINE PROTEINASE; UNCLASSIFIED DRUG; GELATINASE; MEMBRANE PROTEIN; SEPRASE;

ADULT; AGED; ARTICLE; CANCER DIAMETER; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBROBLAST; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; METACHRONOUS LYMPH NODE METASTASIS; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; SYNCHRONOUS LYMPH NODE METASTASIS; GENE EXPRESSION REGULATION; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; GELATINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RETROSPECTIVE STUDIES; SERINE ENDOPEPTIDASES; SURVIVAL ANALYSIS;

EID: 85007499588     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0169105     Document Type: Article

References (40)

1. Siegel RL, Miller KD, Jemal A (2015). Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781. doi: 10.1016/j.ejca.2009.12.014 PMID: 20116997
3. rd edn. Philadelphia: Saunders, 2014: 76-156.
4. Mourad WF, Dutcher J, Ennis RD. State-of-the-art management of renal cell carcinoma. Am J Clin Oncol. 2014; 37(5): 498-505. PMID: 22868246
5. Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3: 49-56.
6. Incorvaia L, Bronte G, Bazan V, Badalamenti G, Rizzo S, Pantuso G et al. Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. Oncotarget 2016; Vol 7,16; 21259-71
7. Li Z, Hao P, Wu Q, Li F, Zhao J, Wu K et al. Genetic mutations associated with metastatic clear cell renal cell carcinoma. Oncotarget 2016; Vol 7,16; 16172-79.
8. Marx J. Cancer biology. All in the stroma: cancer's Cosa Nostra. Science 2008; 320: 38-41. doi: 10.1126/science.320.5872.38 PMID: 18388269
9. Zi F, He J, He D, Li Y, Yang L, Cai Z. Fibroblast activation protein-α in tumor microenvironment: recent progression and implications (Review). Mol Med Rep 2015; 11: 3203-3211. doi: 10.3892/mmr.2015.3197 PMID: 25593080
10. Teichgräber V, Monasterio C, Chaitanya K, Boger R, Gordon K, Dieterle T et al. Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro. Adv Med Sci 2015; 60: 264-272. doi: 10.1016/j.advms.2015.04.006 PMID: 26057860
11. Liu F, Qi L, Liu B, Liu J, Zhang H, Che D et al. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS One 2015
12. Xu Y, Lu Y, Song J, Dong B, Kong W, Xue W et al. Cancer-associated fibroblasts promote renal cell carcinoma progression. Tumour Biol 2015; 36: 3483-3488. doi: 10.1007/s13277-014-2984-8 PMID: 25613067
13. Lopez JI, Errarte P, Erramuzpe A, Guarch R, Cortés JM, Angulo JC et al. Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma. Hum Pathol 2016
14. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663. PMID: 7180965
15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, 7th Edition Springer; 2010.
16. Dabestani S, Thorstenson A, Lindblad P, Harmenberg U, Ljungberg B, Lundstam S. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol 2016
17. Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol 2010; 28: 319-327. doi: 10.1007/s00345-010-0540-8 PMID: 20364259
18. Semeniuk-Wojtas A, Stec R, Szczylik C. Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer? Urologic Oncology: seminars and original investigations 2016; 34: 215-220. doi: 10.1016/j.urolonc.2015.12.013 PMID: 26850779
19. Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ et al. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. Eur Urol 2015; 68: 506-15. doi: 10.1016/j.eururo.2014.11.054 PMID: 25524810
20. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015; 67: 913-24. doi: 10.1016/j.eururo.2015.01.005 PMID: 25616710
21. Kelly T, Huang Y, Simms AE, Mazur A. Fibroblast activation protein-a: a key modulator of the microenvironment in multiple pathologies. Int Rev Cell Mol Biol 2012; 297: 83-116. doi: 10.1016/B978-0-12-394308-8.00003-0 PMID: 22608558
22. Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Ku JH. Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. Tumori 2007; 93: 68-74. PMID: 17455874
23. Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S et al. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? J Exp Clin Cancer Res 2015; 34: 10. doi: 10.1186/s13046-015-0122-0 PMID: 25651794
24. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48: 7310-3. PMID: 3056613
25. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005; 174: 1759-63. doi: 10.1097/01.ju.0000177487.64651.3a PMID: 16217278
26. Escudier B, Choueiri TK, Oudard S, Szczylik C, Négrier S, Ravaud A et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol. 2007; 178: 1901-5. doi: 10.1016/j.juro.2007.07.035 PMID: 17868728
27. Montel V, Mose ES, Tarin D. Tumor-stromal interactions reciprocally modulate gene expression patterns during carcinogenesis and metastasis. Int J Cancer 2006 119: 251-263. doi: 10.1002/ijc.21757 PMID: 16482564
28. Mundim FGL, Pasini FS, Nonogaki S, Rocha RM, Soares FA, Brentani MM et al. Breast carcinoma-associated fibroblasts share similar biomarker profiles in matched nymph node metastasis. Appl Immunohistochem Mol Morphol 2016.
29. Augoff K, Hryniewicz-Jankowska, Tabola R, Czapala L, Szelachowski P, Wierzbicki J et al. Upregulated expression and activation of membrane-associated proteases in esophageal squamous cell carcinoma. Oncology reports 2014; 31: 2820-2826. doi: 10.3892/or.2014.3162 PMID: 24789592
30. Baird S, Allan L, Renner C, Scott FE, Scott AM. Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways. Clin Exp Metastasis 2015; 32: 507-516. doi: 10.1007/s10585-015-9723-4 PMID: 25995078
31. Varona A, Blanco L, Perez I, Gil J, Irazusta J, Lopez JI et al. Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent. BMC Cancer 2010; 10: 193. doi: 10.1186/1471-2407-10-193 PMID: 20459800
32. Larrinaga G, Blanco L, Sanz B, Perez I, Gil J, Unda M et al. The impact of peptidase activity in clear cell renal cell carcinoma survival. Am J Physiol Renal Physiol 2012; 303: F1584-1591. doi: 10.1152/ajprenal.00477.2012 PMID: 23019229
33. Piva F, Giuletti M, Santoni M, Occhipinti G, Scarpelli M, López-Beltran A et al. Epithelial to mesenchymal transition in renal cell carcinoma: implications for cancer therapy. MolDiagn Ther 2016; 20: 111-117. doi: 10.1007/s40291-016-0192-5 PMID: 26940073
34. Boström AK, Möller C, Nilsson E, Elfving P, Axelson H, Johansson ME. Sarcomatoid conversion of clear cell renal cell carcinoma in relation to epithelial-to-mesenchymal transition. Human Pathology 2012; 43: 708-719. doi: 10.1016/j.humpath.2011.06.019 PMID: 21992819
35. Zhou B, Chen WL, Wang YY, Lin ZY, Zhang DM, Fan S et al. A role for cancer-associated fibroblasts in inducing the epithelial-to-mesenchymal transition in human tongue squamous cell carcinoma. J Oral Pathol Med 2014; 43: 585-92. doi: 10.1111/jop.12172 PMID: 24645915
36. Rüger R, Tansi FL, Rabenhold M, Steiniger F, Kontermann RE, Fahr A et al. In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes. J Control Release 2014; 28; 186: 1-10.
37. Tansi FL, Rüger R, Böhm C, Kontermann RE, Teichgraeber UK, Fahr A et al. Potential of activatable FAP-targeting immunoliposomes in intraoperative imaging of spontaneous metastases. Biomaterials 2016; 88: 70-82. doi: 10.1016/j.biomaterials.2016.02.028 PMID: 26945457
38. Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst 2012; 104: 1320-34. doi: 10.1093/jnci/djs336 PMID: 22911669
39. Brennen WN, Rosen DM, Chaux A, Netto GJ, Isaacs JT, Denmeade SR. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. Prostate 2014; 74(13): 1308-19. doi: 10.1002/pros.22847 PMID: 25053236
40. Brennen WN, Kisteman LN, Isaacs JT. Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures. Prostate 2016; 76(6): 552-64. doi: 10.1002/pros.23145 PMID: 26732992